Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06439225 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Study acronym: OPTION-DDR
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 59 wordsv19
  2. Site details revised at 1 of 14 sitesv18
  3. Re-verified, no change to tracked fieldsv17
  4. Study sites: 13 to 14v16
  5. Site details revised at 2 of 13 sitesv15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 9 to 13v14
  2. Study sites: 8 to 9v13
  3. Study sites: 6 to 8v12
  4. Study sites: 5 to 6v11
  5. Study sites: 4 to 5v10
  6. Eligibility criteria expanded, about 35 wordsv9
  7. Study sites: 1 to 4v8
  8. Start date: Dec 20, 2024 to Dec 30, 2024v7
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 31, 2025 to Dec 20, 2024
    • Site details revised
    v6
  10. Start date: Nov 30, 2024 to Jan 31, 2025v5
  11. Study sites: 0 to 1v4
  12. Start date: Sep 30, 2024 to Nov 30, 2024v3
  13. Start date: Jul 31, 2024 to Sep 30, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach? This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.
Trial Details
NCT Number NCT06439225
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions
(from sponsor)		 Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 236 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov